Methotrexate for primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Methotrexate has been used to treat patients with primary biliary cirrhosis as it possesses immunosuppressive properties. The previously prepared version of this review from 2005 showed that methotrexate seemed to significantly increase mortality in patients with primary biliary cirrhosis. Since that last review version, follow-up data of the included trials have been published. OBJECTIVES: To assess the beneficial and harmful effects of methotrexate for patients with primary biliary cirrhosis. SEARCH STRATEGY: Randomised clinical trials were identified by searching The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, and EMBASE (from their inception until September 2009). Reference lists were also read through. Authors of trials were contacted. SELECTION CRITERIA: We searched to include randomised clinical trials comparing methotrexate with placebo, no intervention, or another drug irrespective of blinding, language, year of publication, or publication status. DATA COLLECTION AND ANALYSIS: Our primary outcomes were mortality, and mortality or liver transplantation combined. Dichotomous outcomes were reported as relative risks (RR) and hazard ratios (HR) if applicable. Continuous outcomes were reported as mean differences (MD). MAIN RESULTS: Five trials were included. Four trials with 370 patients compared methotrexate with placebo or no intervention (three trials added an equal dose of ursodeoxycholic acid to the intervention groups). The bias risk of these trials was high. We did not find statistically significant effects of methotrexate on mortality (RR 1.32, 95% CI 0.66 to 2.64), mortality or liver transplantation combined, pruritus, fatigue, liver complications, liver biochemistry, liver histology, or adverse events. The pruritus score (MD - 0.17, 95% CI - 0.25 to - 0.09) was significantly lower in patients receiving methotrexate. The prothrombin time was significantly worsened in patients receiving methotrexate (MD 1.60 s, 95% CI 1.18 to 2.02). One trial with 85 patients compared methotrexate with colchicine. The trial had low risk of bias. Methotrexate, when compared to colchicine, did not significantly effect mortality, fatigue, liver biopsy, or adverse events. Methotrexate significantly benefited pruritus score (MD - 0.68, 95% CI - 1.11 to - 0.25), serum alkaline phosphatases (MD - 0.41 U/l, 95% CI - 0.70 to - 0.12), and plasma immunoglobulin M (MD - 0.47 mg/dl, 95% CI - 0.74 to - 0.20) compared with colchicine. Other outcomes showed no statistical difference. AUTHORS' CONCLUSIONS: Methotrexate had no statistically significant effect on mortality in patients with primary biliary cirrhosis nor the need for liver transplantation. Although methotrexate may benefit other outcomes (pruritus score, serum alkaline phosphatase, immunoglobulin M levels), there is no sufficient evidence to support methotrexate for patients with primary biliary cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Self-citationWhat is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
A comparison of methods to detect publication bias in meta‐analysis
Macaskill, P., Walter, S. D., & Irwig, L. (2001) · Statistics in Medicine · doi:10.1002/sim.698 · Cited by 1,286
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Natural history of early primary biliary cirrhosis
Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421
Epidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Mayo, M. J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A. S., Markin, R. S., Rubin, R., Wheeler, D., Contos, M., West, A. B., et al. (2008) · Hepatology · doi:10.1002/hep.22517 · Cited by 198
Cited by
Clinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
“A number of studies evaluating methotrexate have had conflicting results and raised concerns that methotrexate may worsen mortality [71–73].”
BackgroundEmpirical Evaluation of Very Large Treatment Effects of Medical Interventions
Pereira, T. V., Horwitz, R. I., & Ioannidis, J. P. A. (2012) · JAMA · doi:10.1001/jama.2012.13444 · Cited by 257
Autoimmune liver disease, autoimmunity and liver transplantation
Carbone, M., & Neuberger, J. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.020 · Cited by 250
Risk of liver disease in methotrexate treated patients
Conway, R., & Carey, J. J. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i26.1092 · Cited by 170
The diagnosis of primary biliary cirrhosis
Bowlus, C. L., & Gershwin, M. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.041 · Cited by 162
Mayo, M. J., Wigg, A. J., Leggett, B. A., Arnold, H., Thompson, A. J., Weltman, M., Carey, E. J., Muir, A. J., Ling, L., Rossi, S. J., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1209 · Cited by 125
Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis
Lindor, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmct074694 · Cited by 115
Metadata
- Authors
- Giljaca, V., Poropat, G., Stimac, D., & Gluud, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-05-12
- Volume
- 2010
- Issue
- 5
- Pages
- CD004385-CD004385
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1921711992
- Cited by
- 54
- References
- 15
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.